A Phase 2B, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Japanese Subjects With Moderate-To-Severe Plaque-Type Psoriasis

A Phase 2B, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Japanese Subjects With Moderate-To-Severe Plaque-Type Psoriasis

Completed

Phase of Trial:
Phase II

Latest Information Update:03 Mar 2017

At a glance

Drugs
Apremilast (Primary)

Indications
Plaque psoriasis; Psoriatic arthritis

Focus
Registrational; Therapeutic Use

Sponsors
Celgene Corporation

Most Recent Events

07 Jun 2017
Biomarkers information updated

03 Mar 2017
According to a Celgene Corporation media release, data from this trial will be presented at the 75th Annual Meeting of the American Academy of Dermatology (AAD).

20 Dec 2016
According to a Celgene Corporation media release, Japan's Ministry of Health, Labor and Welfare (MHLW) granted a full marketing authorisation to apremilast [Otelza] for the treatment of adult patients with plaque psoriasis based on data from this study and other three studies (PSOR-005, ESTEEM-1 and 2).

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login
with a username/password associated to an account with a valid subscription